Anaptysbio (ANAB) Enterprise Value (2016 - 2026)
Anaptysbio's (ANAB) quarterly Enterprise Value came in at -$286.5 million in Q1 2026, up 15.73% YoY from -$247.5 million in Q1 2025, and up 8.08% on a QoQ basis from -$311.6 million in Q4 2025.
Anaptysbio (ANAB) Enterprise Value (2016 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 11 years of Enterprise Value data on file, last reported at -$286.5 million in Q1 2026.
- Quarterly Enterprise Value rose 15.73% year-over-year to -$286.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$286.5 million (up 15.73% YoY) and the FY2025 annual result came in at -$311.6 million, up 19.13% from the prior year.
- Enterprise Value improved to -$286.5 million in Q1 2026, from -$311.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$249.0 million in Q3 2025 to a low of -$505.6 million in Q1 2022.
- A 5-year average of -$380.6 million and a median of -$390.9 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2022 — Enterprise Value sank 33.05% — and 2025, when it soared 42.12%.
- Tracing ANAB's Enterprise Value over 5 years: stood at -$441.2 million in 2022, then grew by 11.41% to -$390.9 million in 2023, then rose by 1.41% to -$385.4 million in 2024, then climbed by 19.13% to -$311.6 million in 2025, then advanced by 8.08% to -$286.5 million in 2026.
- The last three Enterprise Value figures came in at -$286.5 million (Q1 2026), -$311.6 million (Q4 2025), and -$249.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | -286.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -286.46 Mn |
| Dec 31, 2025 | -311.64 Mn |
| Sep 30, 2025 | -248.96 Mn |
| Jun 30, 2025 | -265.71 Mn |
| Mar 31, 2025 | -339.94 Mn |
| Dec 31, 2024 | -385.37 Mn |
| Sep 30, 2024 | -430.12 Mn |
| Jun 30, 2024 | -350.80 Mn |
| Mar 31, 2024 | -354.67 Mn |
| Dec 31, 2023 | -390.90 Mn |
| Sep 30, 2023 | -413.05 Mn |
| Jun 30, 2023 | -429.49 Mn |
| Mar 31, 2023 | -431.15 Mn |
| Dec 31, 2022 | -441.24 Mn |
| Sep 30, 2022 | -442.97 Mn |
| Jun 30, 2022 | -442.15 Mn |
| Mar 31, 2022 | -505.62 Mn |
| Dec 31, 2021 | -548.10 Mn |
| Sep 30, 2021 | -336.39 Mn |
| Jun 30, 2021 | -332.31 Mn |